Kennedy B, Gargoum F, Bystricky B, Curran DR and O'Connor TM: Novel agents in the management of lung cancer. Curr Med Chem 17: 4291-325, 2010.
Schiller JH, Harrington D, Balani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH and Eastern Cooperative Oncology Group: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98, 2002.
Tredaniel J, Mornex F, Barillot I, Langer C, Diaz O, Hennequin C, Le Pechoux C, Lavole A, Giraud P, Souquet PJ, Teixeira L, Vaylet F, Zalcman G, Baudrin L, Morin F and Milleron B: A phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non squamous, non-small cell lung cancer (NSCLC). Rev Mal Respir 28: 51-57, 2011.
De Boer RH, Arrieta O, Yang CH, Gottfried M, Chan V, Raats J, de Marinis F, Abratt RP, Wolf J, Blackhall FH, Langmuir P, Milenkova T, Read J and Vansteenkiste JF: Vandetanib plus pemetrexed for the second line treatment of advanced non-small-cell lung cancer. A randomized, double-blind phase III trial. J Clin Oncol 29: 1067-1074, 2011.
Dubey S and Schiller JH: The emerging new drugs for NSCLC: pemetrexed, bortezomib and cetuximab. Oncologist 10: 282-291, 2005.
Goldman ID, Chattopadhyay S, Zhao R and Moran R: The antifolates: evolution, new agents in the clinic, and how targeting delivery via specific membrane transporters is driving the development of a next generation of folate analogs. Curr Opin Invest Drugs 11: 1409-1423, 2010.
Hagner N and Joerger M: Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res 19: 293-301, 2010.
Wu MF, Hsiao YM, Huang CF, Huang YH, Yang WJ, Chan HW, Chang JT and Ko JL: Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells. J Thorac Oncol 5: 1143-1151, 2010.
Zucali PA, Giovannetti E, Destro A, Mencoboni M, Ceresoli GL, Gianoncelli L, Lorenzi E, de Vincenzo F, Simonelli M, Perrino M, Bruzzone A, Thunnissen E, Tunesi G, Giordano L, Roncalli M, Peters GJ and Santoro A: Thymidylate synthase and excision repair-cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed-carboplatin. Clin Cancer Res 17: 2581-2590, 2011.
Shih C, Habeck LL, Mendelsohn LG, Chen VJ and Schultz RM: Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul; 38: 135-152, 1998.
Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M and Schultz RM: LY231514, a pyrrolo(2,3-d)-pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57: 1116-1123, 1997.
Racanelli AC, Rothbart SB, Heyer CL and Moran RG: Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res 69: 5467-5474, 2009.
Calvert AH: Biochemical pharmacology of pemetrexed. Oncology 18: S13-S17, 2004.
Dickgreber NJ, Sorensen JB, Paz-Ares LG, Schytte TK, Latz JE, Schneck KB, Yuan Z and Sanchez-Torres JM: Pemetrexed safety and pharmacokinetics in patients with third-space fluid. Clin Cancer Res 16: 2872-2880, 2010.
Brandes JC, Grossman SA and Ahmad H: Alteration of pemetrexed excretion in the presence of acute renal failure and effusions: presentation of a case and review of the literature. Cancer Invest 24: 283-287, 2006.
Niyikiza C, Baker SD, Seitz DE, Walling JM, Nelson K, Rusthoven JJ, Stabler SP, Paoletti P, Calvert AH and Allen RH: Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 1: 545-552, 2002.
Belli C, Fennell D, Giovannini M, Gaudino G and Mutti L: Malignant pleural mesothelioma: current treatments and emerging drugs. Expert Opin Emerg Drugs 14: 423-437, 2009.
Zalcman G, Bergot E and Lechapt E: Pemetrexed re-challenge in pleural malignant mesothelioma: an option for a subset of patients initially treated with pemetrexed-platinum doublets in the first-line setting? Lung Cancer 72: 1-2, 2011.
Cohen MH, Cortazar P, Justice R and Pazdur R: Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC). Oncologist 15: 1352-1358, 2010.
Edelman MJ, Otterson G, Leach J, Malpass T, Salgia R, Jones D, Mody TD and Govindan R: Multicenter phase II trial of motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer. J Thorac Oncol 6: 786-789, 2011.
Gridelli C, Maione P, Rossi A, Bareschino MA, Schettino C, Sacco PC and Zeppa R: Pemetrexed in advanced non-small cell lung cancer. Expert Opin Drug Saf 10: 311-317, 2011.
Clarcke SJ, Abratt R, Goedhals L, Boyer MJ, Millward MJ and Ackland SP: Phase II trial of pemetrexed disodium in chemotherapy-naïve patients with advanced non-small-cell lung cancer. Ann Oncol 13: 737-741, 2002.
Niyikiza C, Hanauske AR, Rusthoven JJ, Calvert AH, Allen R, Paoletti P and Bunn PA Jr: Pemetrexed safety and dosing strategy. Semin Oncol 29: 24-29, 2002.
Bracke A, van Marck E and Lambert J: Acute generalized exanthematous pustulosis after pemetrexed, and recurrence after re-introduction. Clin Exp Dermatol 34: 337-339, 2008.
Lopes G, Vincek V and Raez L: Pemetrexed associated urticarial vasculitis. Lung Cancer 51: 247-249, 2006.
Hureaux J, Le Guen Y, Tuchais C, Savary L and Urban T: Radiation recall dermatitis with pemetrexed. Lung Cancer 50: 255-258, 2005.
Barlési F, Tummino C, Tasei AM and Astoul B: Unsuccessful rechallenge with pemetrexed after a previous radiation recall dermatitis. Lung Cancer 54: 423-425, 2006.
Spirig C, Omlin A, D'Addario G, Lose KD, Esenwein P, Geismar JH and Ruhstaller T: Radiation recall dermatitis with soft tissue necrosis following pemetrexed therapy: a case report. J Med Case Reports 2: 93, 2009.
Tummino C, Barlesi F, Tchouhadjian C, Tasei AM, Gaudy-Marqueste C, Richard MA and Astoul P: Severe cutaneous toxicity after pemetrexed as a second line treatment for a refractory non small cell lung cancer. Rev Mal Respir 24: 635-638, 2007.
Bosch-Barrera J, Gaztanaga M, Ceballos J, Pérez-Gracia JL, Lopez-Picazo JM, Garcia-Foncillas J, Ferrer M, Sanz ML, Pretel M, Idoate MA and Gil-Bazo I: Toxic epidermal necrolysis related to pemetrexed and carboplatin with vitamin B12 and folic acid supplementation for advanced non-small cell lung cancer. Onkologie 32: 580-584, 2009.
Schallier D, Decoster L, Fontaine C and de Grève J: Pemetrexed-induced eyelid edema: incidence and clinical manifestations. Anticancer Res 30: 5185-5188, 2010.
Sabatiello M, Willemaers V, Lesuisse M and Piérard GE: Pemetrexed-induced pityriasis lichenoides-like dermatitis. J Eur Acad Dermatol Venereol (In press).
Franchimont C and Piérard GE: Cutaneous pathobiology mediated by chemotherapy. J Cutan Pathol 7: 387-393, 1980.
Stone N, Sheerin S and Burge S: Toxic epidermal necrolysis and graft vs. host disease: a clinical spectrum but a diagnostic dilemma. Clin Exp Dermatol 24: 260-262, 1999.
Paquet P, Jacob E, Pirson J and Piérard GE: Drug-induced toxic epidermal necrolysis and pancytopenia: A puzzling association. Int J Mol Med 16: 29-33, 2005.
Sawada Y, Kawakami C, Nakamura M, Tokura Y and Yoshiki R: Toxic epidermal necrosis-like dermatosis induced by the first course of methotrexate. Eur J Dermatol 19: 397-398, 2009.
Paquet P and Piérard GE: New insights in toxic epidermal necrolysis (Lyell's syndrome). Clinical considerations, pathobiology and targeted treatments revisited. Drug Saf 33: 189-212, 2010.
Piérard GE and Paquet P: Facing up to toxic epidermal necrolysis. Exp Opin Pharmacother 11: 2443-2446, 2010.
Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y, Bork K, Haustein UF, Vieluf D, Roujeau JC and le Louet H: ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 88: 60-68, 2010.
Isoda M: Pityriasis lichenoides-like eruption occurring during therapy for myelogenous leukaemia. J Dermatol 16: 73-75, 1989.
Bowers S and Warshaw E: Pityriasis lichenoides and its subtypes. J Am Acad Dermatol 55: 557-572, 2006.
Khachemoune A and Blyumin M: Pityriasis lichenoides. Am J Clin Dermatol 8: 29-36, 2007.
Nikkels AF, Gillard P and Piérard GE: Etanercept in therapy-multiresistant pityriasis lichenoides, overlapping type. J Drugs Dermatol 7: 923-925, 2008.
Quatresooz P and Piérard GE: Dermal dendrocyte ballooning. Am J Clin Dermatol 7: 391-392, 2006.
Kano Y, Tanaka M, Akutsu M, Mori K, Yazawa Y, Mano H and Furukawa Y: Schedule-dependent synergism and antagonism between pemetrexed and docetaxel in human lung cancer cell lines in vitro. Cancer Chemother Pharmacol 64: 1129-1137, 2009.
Quatresooz P and Piérard GE: A docetaxel-induced rash on a radiotherapy port. Am J Clin Dermatol 11: 367-369, 2010.
Paquet P, Vandenbossche G, Nikkels AF, Henry F and Piérard GE: Acute generalized exanthematous pustulosis due to an iodinated contrast radiodiagnostic agent. Rev Med Liège 64: 601-605, 2009.
Halevy S, Kardaun SH, Davidovici B, Wechsler J and EuroSCAR and RegiSCAR study group: The spectrum of histopathological features in acute generalized exanthematous pustulosis: a study of 102 cases. Br J Dermatol 163: 1245-1252, 2010.
Quatresooz P, Rorive A, Paquet P, Piérard-Franchimont C and Piérard GE: Cutaneous adverse effects predicting the efficacity of targeted antineoplastic therapies. Rev Med Liège 64: 247-350, 2009.
Hermanns JF, Piérard GE and Quatresooz P: Erlotinib-responsive actinic keratoses. Oncol Reports; 18: 581-584, 2007.
Piérard GE, Paquet P, Piérard-Franchimont C, Rorive A and Quatresooz P: Cutaneous adverse reactions to chemotherapy and their management. Rev Med Liège 62: 457-462, 2007.
